Dr. Swisher on the Phase III VELIA Results in Ovarian Cancer


Elizabeth M. Swisher, MD, discusses results from the phase III VELIA/GOG-3005 trial in ovarian cancer.

Elizabeth M. Swisher, MD, a co-leader of the Breast and Ovarian Cancer Research Program at Seattle Cancer Care Alliance, a professor in the Division of Gynecologic Oncology at the University of Washington School of Medicine, director of Division of Gynecologic Oncology at UW Medicine, and affiliate investigator in the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses results from the phase III VELIA/GOG-3005 trial in ovarian cancer.

In this phase III trial, the combination of veliparib and chemotherapy showed significant improvement in progression-free survival (PFS) for patients with BRCA mutations and are positive for homologous recombination deficiency.

Patients were evenly randomized amongst 3 arms to veliparib plus induction carboplatin and paclitaxel either with or without veliparib maintenance, or a control arm of induction chemotherapy with no maintenance. Unfortunately, no benefit was recognized in the arm that explored veliparib plus chemotherapy followed by placebo maintenance compared with chemotherapy with placebo maintenance. The benefits were limited to the arms that received maintenance veliparib, Swisher concludes.

Related Videos
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
Timothy Yap, MBBS, PhD, FRCP
Muhamed Baljevic, MD, FACP
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD